In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

Vertex Pharmaceuticals (VRTX) shares soared 5.3% in the last trading ... Revenues are expected to be $2.77 billion, up 10.2% from the year-ago quarter. While earnings and revenue growth ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had ... The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The firm has a market ...

Our analysis of options history for Vertex Pharmaceuticals VRTX revealed 10 unusual trades. Delving into the details, we found 20% of traders were bullish, while 80% showed bearish tendencies.

Vertex Pharmaceuticals (VRTX) shares soared 5.3% in the last trading session to close at $461.68. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

The upcoming report from Vertex Pharmaceuticals (VRTX) is expected to reveal quarterly earnings of $3.99 per share, indicating a decline of 5% compared to the year-ago period. Analysts forecast ...

Phase 2 LSR trial showed minimal benefit vs placebo, raising concerns about $11B peak sales estimates and success in ongoing diabetic neuropathy trial (completion in 2027). Conservative market ...